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Abstract
Background: Infestations of the parasitic copepod Lepeophtheirus salmonis, commonly referred to as sea lice, represent a
major challenge to commercial salmon aquaculture. Dependence on a limited number of theraputants to control such
infestations has led to concerns of reduced sensitivity in some sea lice populations. This study investigates trends in the
efficacy of the in-feed treatment emamectin benzoate in Scotland, the active ingredient most widely used across all salmon
producing regions.
Methodology/Principal Findings: Study data were drawn from over 50 commercial Atlantic salmon farms on the west coast
of Scotland between 2002 and 2006. An epi-informatics approach was adopted whereby available farm records, descriptive
epidemiological summaries and statistical linear modelling methods were used to identify factors that significantly affect
sea lice abundance following treatment with emamectin benzoate (SLICEH, Schering Plough Animal Health). The results
show that although sea lice infestations are reduced following the application of emamectin benzoate, not all treatments
are effective. Specifically there is evidence of variation across geographical regions and a reduction in efficacy over time.
Conclusions/Significance: Reduced sensitivity and potential resistance to currently available medicines are constant threats to
maintaining control of sea lice populations on Atlantic salmon farms. There is a need for on-going monitoring of emamectin
benzoate treatment efficacy together with reasons for any apparent reduction in performance. In addition, strategic rotation of
medicines should be encouraged and empirical evidence for the benefit of such strategies more fully evaluated.
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Introduction
Commercial farming of Atlantic salmon (Salmo salar L) has
developed rapidly since the 1970’s, with global production
exceeding one million tonnes per annum since 2002 [1]. Atlantic
salmon farming is currently dominated by the aquaculture
industries of Norway and Chile, however Scotland and Canada
are also major producers.
As intensive marine aquaculture developed, the threat posed to
fish health and production by infestations of parasitic copepods
emerged as one of the greatest challenges facing the industry [2].
Not only can these aquatic parasites inhibit growth and cause
extensive damage, extreme infestation can lead to host mortality
[3]. It has also been suggested that caligid copepods, commonly
referred to as sea lice, originating from salmon farms may pose a
risk to wild salmonid populations [4–8].
In Scotland two species of sea lice parasitise farmed salmonids:
Lepeophtheirus salmonis (Krøyer 1837) and Caligus elongatus (Nord-
mann 1832). Of the two species, L. salmonis is the larger and more
abundant [9]. Whereas C. elongatus is known to parasitise more
than 80 species of fish, the major species of interest L. salmonis is
principally confined to salmonids [10].
In response to the challenges presented by sea lice infestation,
salmon producers on the west coast of Scotland have developed
integrated health management programmes based on previous
research into the epidemiology of sea lice [11–14] and farm
management practices [15–18]. Some of these management
strategies have proven to be successful and, together with the
availability of more effective ectoparasitic medicines, have helped
to reduce the abundance of L. salmonis and C. elongatus on Scottish
farms over the past decade [19]. Nevertheless, sea lice remain a
persistent problem and the cost of controlling these parasites is
substantial [18].
The availability and use of medicines to control sea lice burdens
in Scotland has changed considerably in the last decade and since
2005 only two therapeutants have been in common use; the
topical treatment cypermethrin (ExcisH, Novartis Animal Health)
and the in-feed treatment emamectin benzoate (SLICEH, Schering
Plough Animal Health). Both ectoparasiticides are widely used
and, since obtaining UK Market Authorisation in 2000, the use of
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While both medicines are effective against all parasitic stages of sea
lice, the major advantage of emamectin benzoate is that it can
offer sustained periods of louse clearance [20–22]. Furthermore, as
an in-feed therapeutant, it can be safely and effectively
administered during adverse weather conditions and whole sites/
loch systems can be medicated in a coordinated manner.
Cypermethrin bath treatments are more labour intensive and
can be stressful to the fish; these interventions are applied more
frequently toward the end of the production cycle when salmon
are larger and in-feed treatments are consequently more costly.
In Canada, emamectin benzoate (SLICEH) is available under
Emergency Drug Release and another in-feed medicine, teflu-
benzuron (CalicideH, Skretting), has an INAD (Investigational
New Animal Drug) approval. However, salmon producers in
British Columbia only have access to emamectin benzoate [23].
Until recently, various brands of emamectin benzoate were the
only sea lice medicines available in Chile, but the topical treatment
deltamethrin (Alpha MaxH, Pharmaq) was licensed for use in late
2007. It should be noted that Atlantic farmed salmon in this region
are parasitised by Caligus rogercresseyi (Boxshall and Bravo 2000)
rather than L. salmonis and C. elongatus. Dependence on such a
limited range of ectoparasiticides has raised concerns that
resistance in lice will become an increasing problem for salmon
farmers unless new medicines become available and/or existing
therapeutants are appropriately managed [24,25]. While there
have been anecdotal reports of reduced sensitivity and potential
resistance of sea lice to emamectin benzoate, particularly in Chile,
few published studies have examined the efficacy of emamectin
benzoate on infestations of L. salmonis in farmed Atlantic salmon
since regular treatment began in Scotland in 2002 [26,27].
As described in a recent report by Gustafson et al [28], efficacy
studies usually rely on the availability of an untreated control
group with which to compare medicated subjects. However, in a
commercial farm setting where untreated salmon could suffer
extensive damage from sea lice infestation this option can rarely be
justified. In this situation an alternative strategy is to monitor on-
going efficacy by comparing post-treatment lice abundance with
levels recorded prior to treatment intervention [23,26,28].
Using an epi-informatics approach, this study aims to examine
the efficacy of emamectin benzoate against infestations of the
mobile stages of L. salmonis in a commercial setting over a five-year
period. Through examining sea lice abundance and treatment
records drawn from over 50 salmon farms located along the west
coast of Scotland between 2002 and 2006, this study identifies
factors associated with the efficacy of emamectin benzoate
treatment interventions.
Materials and Methods
Data set
Sea lice abundance and treatment data, in addition to site
stocking records, were drawn from 56 commercial Atlantic salmon
(Salmo salar L) farms located along the west coast of Scotland
between 2002 and 2006. As in earlier analyses, [19,29] sites were
divided above and below the 57uN line of latitude and referred to
as ‘‘North’’ and ‘‘South’’ regions respectively. Those sites noted as
‘‘Western Isles’’ included farms on the east coast of South Uist and
on both the east and west coasts of Harris and Lewis. All farms had
implemented an integrated health management programme that
included the routine monitoring of sea lice abundance throughout
the production cycle. All sites were owned and managed by
Marine Harvest (Scotland).
Sites were stocked with a single year class of fish and for the
most part operated an 18 to 24 month production cycle. Typically
farms were stocked between January and June of the first
production year and harvested between August and December
of the second. At some sites, fish were introduced in October and
others were not harvested until spring of the third year.
Occasionally stocks were split at the end of the first production
year. The number of stocked sites varied from year to year, but all
farms were fallowed for a minimum of six weeks between
production cycles.
Treatment records provided the start and end date of each sea
lice treatment episode in addition to the type of medicine(s)
applied and the quantity administered. The number of pens
treated was recorded which, when compared with stocking data,
allowed each episode to be classified as either a full or partial site
treatment. Stocking records also made it possible to categorise
treatments as having taken place in the first or second year of
production. Episodes were further classified by the season in which
they occurred with months grouped together according to mean
sea water temperatures. In this analysis, spring is defined as
February to April; summer as May to July; autumn as August to
October; and winter as November to January. Water temperatures
were lowest in the spring months and highest in the autumn.
Where possible the industrial partner (Marine Harvest)
performed routine lice counts weekly, however because monitor-
ing can at times be logistically difficult, e.g. due to adverse weather
conditions, farms sometimes deviated from this protocol and
observations at some locations became more sporadic. Depending
on the size of the farm, 10 to 30 fish from between two and six
pens were randomly monitored for lice at each sample point
[30,31]. Fish were removed by dip net and anaesthetised before
being visually inspected for lice. Lice counts were classified
according to species with L. salmonis further differentiated by one of
five gender/life-stages: chalimus, pre-adult, adult male, non-gravid
female and gravid female. In the analyses presented here the pre-
adult, adult male, non-gravid female and gravid female stages of L.
salmonis have been aggregated and are reported as L. salmonis
mobiles. The mobile stages, so called due to their ability to move
around and between fish, are the stages against which treatments
are typically targeted as they tend to cause the greatest damage to
the host.
Treatment episode selection
In the period 2002 to 2006, 561 sea lice treatment episodes were
available for analysis, 258 of which included the use of the in-feed
medicine emamectin benzoate (SLICEH). All but one of the sites
studied had at least one treatment episode involving this medicine.
To ensure consistency only site-wide treatment episodes, where
fish in all pens began treatment on the same day, were selected for
inclusion within this analysis. Mixed treatment episodes, where
some pens were medicated with emamectin benzoate and other
pens with a different theraputant, were not included. Treatments
that occurred on sites that did not follow the typical two-year
production cycle, i.e. those that were stocked between July and
August, were also excluded from this analysis because such
treatments could not readily be classified as first or second year
interventions. All emamectin benzoate treatments were adminis-
tered as medicated feed at 50 mgk g
21 fish for 7 consecutive days.
In contrast to some other regions [28], strategic sea lice
treatments are encouraged in Scotland; often in the early spring of
the second year of production [32]. On some occasions, such
interventions are made even when lice levels are low and mean
louse abundance is below treatment-trigger guidelines (see
Table 1). The aim of strategic treatment is to disrupt the life-
cycle of L. salmonis and prevent levels rising in the latter part of the
production cycle. Such treatments are typically co-ordinated
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to minimise the risk for cross infestation amongst sites.
Efficacy calculations
Treatment efficacy was investigated by comparing post-
treatment mobile L. salmonis abundance with levels recorded prior
to treatment intervention. To establish a meaningful pre-treatment
figure with which to compare post-treatment abundance, at least
one lice count had to be available for a site in the 16 day period
prior to treatment. If lice abundance was monitored more than
once during this time, then levels recorded on the date closest to
the point of treatment intervention were used as the baseline. To
permit analysis at various time points after treatment, only
emamectin benzoate episodes where lice levels were monitored in
at least three of the 12 weeks following treatment, or before
another treatment was applied, were included.
Where treatment efficacy is summarised by year, post-treatment
lice abundance was examined in two ways: as mean lice per fish;
and as a percentage of pre-treatment abundance (mean post-
treatment abundance/mean pre-treatment abundance * 100).
When using the latter approach it was important to ensure that the
percentage change was based on matched pre and post-treatment
lice counts. This allowed the percentage change to be estimated for
each seven day period in the 83 days following treatment, even
though lice levels were not always monitored at all treated sites
every week or for the full 12 weeks following treatment. It should
be noted that not all treatment episodes included in this analysis
were deemed to have been ‘‘effective’’ (Table 1).
Data management and statistical analysis
Data were stored and managed using a set of structured tables
in Microsoft Access 2003. This application was also used to
calculate the mean sea lice abundance values and post-treatment
lice abundance as a percentage of pre-treatment levels. All figures
were constructed using Microsoft Excel 2003 while statistical
analyses were performed within Minitab 14.1.
A statistical model to determine the factors affecting post-
treatment lice abundance was investigated using a General Linear
Model (GLM) procedure. Interactions between all available factors
were also examined. As treatment lasted for 7 days (day 0 to 6),
post-treatment abundance was only analysed for the 7 to 83 day
period following treatment initiation. To improve normality and
equalise variances, data were logarithmically transformed (ln(x+1))
prior to GLM analysis. To aid interpretation of the final models,
least squares means and their 95% confidence intervals were
subsequently untransformed.
Results
The sea lice treatment screening process resulted in a data set
containing 185 emamectin benzoate treatment episodes, 77 of
which did not have the necessary pre/post treatment sea lice data
required for further efficacy analysis. Of the remaining 108
treatments, 22 were followed-up with another sea lice treatment
(either cypermethrin or emamectin benzoate) within 12 weeks.
A summary of the treatment episodes in each of the data sets is
presented in Table 2. The number of treatment episodes, and sites
on which they were administered, varied over the five-year period
studied. However, the majority (84%) of sites studied were
represented in the final data set used for efficacy analysis.
As shown in Figure 1, the profiles of the full and the reduced
data sets were broadly similar. In the first year of production the
majority of emamectin benzoate treatments were administered in
the autumn (Aug–Oct) whereas in the second year most occurred
in the spring (Feb–Apr). Few episodes occurred in spring of the
first year or winter (Nov–Jan) of the second. The main distinction
between the full and the reduced data sets was the proportion of
episodes administered in the autumn of the second production
year. Several of the emamectin benzoate treatments applied in this
period had to be discounted from the efficacy analysis because
Table 1. Definition of terms used within emamectin benzoate efficacy analysis.
Term Definition
Emamectin benzoate treatment: Any site-wide treatment episode where emamectin benzoate was the only sea lice medicine administered and all pens commenced
treatment on the same day.
Effective treatment: Any emamectin benzoate treatment where the mean abundance of mobile L. salmonis fell below 40% of pre-treatment levels in the
12 weeks following treatment. Note: All treatments that were applied before guideline treatment-trigger lice levels had been
reached were classified as effective.
Loch-wide treatment: All stocked farms (owned by the industrial partner) within a loch system were treated for sea lice within two weeks of each other.
The sea lice medicine used at the other sites in the loch system was not necessarily emamectin benzoate.
Effective loch-wide treatment: Any effective treatment that was administered as part of a loch-wide intervention. The sea lice medicine used at the other sites in the
loch system was not necessarily emamectin benzoate. The treatment episodes at the other sites in the loch system were not
necessarily effective.
Treatment-trigger guidelines: Mean abundance of L. salmonis adult females has reached 0.5 (February to June), or 1.0 (July to January).
doi:10.1371/journal.pone.0001549.t001
Table 2. Numbers of sites and episodes of emamectin
benzoate treatment in years 2002 to 2006.
All treatments
Treatments with necessary
pre/post treatment sea lice
data
Year No. of sites
No. of
episodes No. of sites
No. of
episodes
2002 22 26 10 10
2003 24 31 18 21
2004 35 56 24 31
2005 31 47 25 30
2006 17 25 13 16
All 54 185 47 108
Figures are presented for all site-wide emamectin benzoate treatment episodes
and for episodes with the necessary pre/post treatment sea lice data required
for further analysis.
doi:10.1371/journal.pone.0001549.t002
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within a matter of weeks. The other difference of note was the
lower proportion of effective treatments present within the
reduced data set. However, of the 77 treatments that were
excluded from further analysis, it remains unclear how effective
they were due to limited lice count data prior to and/or following
treatment. Similarly, without a valid pre-treatment lice count, it
could not be ascertained how many adult female lice were present
and therefore whether guideline treatment-trigger levels had been
reached. Thus the proportions shown for the full data set should
be regarded as estimates, as the true incidence of effective episodes
may have been lower and the frequency with which treatments
were applied when lice levels were below trigger guidelines may
have been higher.
Trends in treatment efficacy
The mean annual efficacy of emamectin benzoate treatments in
controlling infestations of mobile L. salmonis, in the 83 day period
following treatment initiation, is shown in Figure 2. It should be
noted that efficacy percentages could not be calculated for
episodes with a pre-treatment mobile abundance of zero. This
resulted in four treatment episodes from 2004 and three from 2003
being excluded from this summary plot.
With the exceptionof2006,mean louse abundance inallyearsfell
to less than 45% of pre-treatment levels within 27 days of treatment
intervention. In 2002, abundance fell below 1% of pre-treatment
levels within 34 days and remained lower than 12% throughout the
rest of the 83 day period. Treatments applied in 2003 also appeared
to be highly efficacious, with abundance falling below 5% between
days 28–34, and not rising above 40% thereafter. Treatments
administered in 2004 and 2005 appeared to take longer to reach
maximum efficacy, however mean abundance did fall below 17%
and 30% of pre-treatment abundance respectively. In contrast to all
other years, lice abundance in 2006 remained above pre-treatment
levels until around 5 weeks after treatment intervention. While
abundance did drop to 35% of pre-treatment levels between days 56
and 62, it remained above 40% in all other weeks.
The percentage changes, as presented in Figure 2, should be
considered together with the absolute mean lice abundance prior
to treatment intervention. As illustrated in Figure 3, mean lice
abundance prior to treatment varied considerably over the five-
year period. At 14.4 and 10.7 lice per fish respectively, the mean
pre-treatment abundance of L. salmonis mobiles in 2003 and 2004
was approximately two to three times higher than in 2002, 2005
and 2006. However, with the exception of 2006, mean abundance
in all years dropped to below four lice per fish within a month of
treatment initiation.
Figure 1. Profile of emamectin benzoate treatment episodes in years 2002 to 2006. Proportions are presented for all site-wide emamectin
benzoate treatment episodes and for episodes with the necessary pre/post treatment sea lice data required for further analysis. (A) The proportion of
treatment episodes occurring in each stage of production/season in the two year production cycle. Seasons are defined as spring [Feb–Apr], summer
[May–Jul], autumn [Aug–Oct] and winter [Nov–Jan]. (B) The proportion of effective, loch-wide and effective loch-wide treatment episodes and the
proportion of treatments applied when lice levels were below treatment-trigger guidelines.
doi:10.1371/journal.pone.0001549.g001
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As was observed in Figures 2 and 3, efficacy appeared to
vary amongst years. However, it was important to consider
other factors that may have influenced post-treatment abundance
such as geographical region, season and stage in the production
cycle.
As shown in Table 3, between 2002 and 2006 emamectin
benzoate treatments were administered to different ages of fish, at
various times of the calendar year and across the North, South and
Western Isles regions of the west coast of Scotland. Some of the
treatments were loch-wide while others were for single farms only.
The statistical model that was developed as part of this study
(Table 4) formally investigates the effect each of these factors had
on the post-treatment abundance of mobile L. salmonis lice. To
take account of differing levels of lice challenge, pre-treatment lice
abundance was also included as a covariate in the model.
In each of the seven-day time periods following treatment that
were analysed, 42% to 68% of treated farms reported lice levels.
Lice counts appeared to become slightly less frequent after day 62,
however it should be noted that around 20% of emamectin
benzoate episodes were followed by an additional sea lice
treatment within the 12 week period and any lice counts recorded
after such an event were discounted from the analysis.
Table 4 gives the results of a GLM analysis of mean sea lice
abundance following emamectin benzoate treatment intervention,
based on all 108 episodes. All variables were found to be
statistically significant (p,0.01) and are listed along with least
squares estimates of post-treatment mobile abundances and their
Figure 2. Efficacy of emamectin benzoate treatments in controlling infestations of mobile Lepeophtheirus salmonis, between 2002
and 2006. Post-treatment mobile L. salmonis abundance as a percentage of pre-treatment abundance (6SE), 7–83 days after commencement of
treatment. Plots based on data from 101 treatment episodes at 47 Atlantic salmon farms in Scotland in the period 2002 to 2006.
doi:10.1371/journal.pone.0001549.g002
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are also listed and are further illustrated in Figure 4.
The factors included in the model accounted for 66% of the
variation observed amongst post-treatment sea lice abundance.
Lice levels per fish subsequent to an ineffective treatment (7.01, CI
[5.95–8.22]) were around 10 times higher than those observed
following an effective episode (0.65, CI [0.55–0.75]) (Table 4).
Overall, mean louse abundance was lowest between days 21 and
62 and levels recorded during this time were found to be
significantly lower than those observed between day 7 and 13
(p,0.01). Post-treatment lice abundance was also found to be
significantly higher in the second year of production when
compared to the first (p,0.01).
Three significant interactions were found amongst the variables
studied. Figure 4A highlights the differences that were observed
between the geographical region in which the treatment was
applied and the year it was administered. Post-treatment
abundance in the Western Isles in 2006 (5.34, CI [4.33–6.53])
was significantly higher (p,0.05) than in any other region and
year combination, except the South in 2003 (4.55, CI [3.62–5.66])
and the South in 2005 (4.15, CI [3.55–4.84]). Post-treatment
abundance in the North, for all years, was significantly lower
(p,0.05) than these three region and year values, except for 2006
(2.40, CI [1.77–3.18]), when it did not differ significantly from the
South in 2005.
Analyses showed that ineffective spring treatments (11.77, CI
[8.07–16.97]) performed significantly worse (p,0.01) than inef-
fective treatments applied in autumn (4.56, CI [3.44–5.97])
(Figure 4B). However, only two of the 30 spring treatments
analysed were categorised as ineffective and the wide confidence
Figure 3. Mean abundance of mobile Lepeophtheirus salmonis, pre and post emamectin benzoate treatment, between 2002 and
2006. Mean mobile L. salmonis abundance (6SE), pre-treatment and 0–83 days after commencement of treatment. Plots based on data from 108
treatment episodes at 47 Atlantic salmon farms in Scotland in the period 2002 to 2006.
doi:10.1371/journal.pone.0001549.g003
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should be treated with caution.
A significant interaction also existed between the season in
which the treatment was applied and loch-wide interventions
(Figure 4C). Lice abundance following winter loch-wide treat-
ments (4.87, CI [3.61–6.46]) was found to be significantly higher
(p,0.05) than after any emamectin benzoate intervention applied
in other seasons, except for loch-wide treatments applied in spring
(3.75, CI [2.79–4.95]).
Discussion
By adopting an epi-informatics approach and examining a large
historical data set, the efficacy of emamectin benzoate treatments
administered over a five year period, at different stages of
production and across three Scottish regions was shown to vary
significantly. While commercial farm records provide a rich source
of information, working with production data can present some
challenges. Only when a large data set is available is it possible to
extract data of sufficient quality and quantity to perform
meaningful analysis. The routine lice monitoring programme that
was in place allowed 58% of the site-wide emamectin benzoate
treatments administered between 2002 and 2006 to be included in
the efficacy analysis. Two previous studies that used production
data to assess the efficacy of emamectin benzoate in British
Columbia [23] and on the Maine coast [28] encountered similar
challenges, with fewer than 20 treatment episodes remaining
Table 3. Percentages of emamectin benzoate episodes
classified according to each of the variables included in the
GLM.
Variable Class % of treatments (N=108)
#Days after treatment 7–13 59%
14–20 68%
21–27 66%
28–34 56%
35–41 67%
42–48 59%
49–55 61%
56–62 58%
63–69 52%
70–76 47%
77–83 42%
Region North 36%
South 33%
Western Isles 31%
Year 2002 9%
2003 19%
2004 29%
2005 28%
2006 15%
Production year 1st 45%
2nd 55%
Season Spring (Feb–Apr) 28%
Summer (May–Jul) 30%
Autumn (Aug–Oct) 30%
Winter (Nov–Jan) 13%
Effective No 18%
Yes 82%
Loch-wide No 53%
Yes 47%
#- ‘‘% of treatments’’ for the variable ‘‘Days after treatment’’ refers to the
percentage of treated farms that were monitored for sea lice in each 7-day
time period following treatment.
doi:10.1371/journal.pone.0001549.t003
Table 4. Results of the GLM analysis of sea lice abundance
following emamectin benzoate treatment.
Post-treatment
mobile abundance
Variable p-value Class
Least
squares
mean 95% CI
# Pre-treatment
mobile abundance
0.00 - - -
Days after treatment 0.00 7–13 3.83 [3.23–4.51]
14–20 2.84 [2.40–3.34]
21–27 2.29 [1.89–2.74]
28–34 2.19 [1.80–2.65]
35–41 2.39 [1.98–2.86]
42–48 2.24 [1.83–2.71]
49–55 2.24 [1.84–2.71]
56–62 2.52 [2.07–3.04]
63–69 2.80 [2.29–3.38]
70–76 2.97 [2.42–3.61]
77–83 2.94 [2.37–3.61]
Region 0.00 North 2.08 [1.79–2.39]
South 3.10 [2.68–3.58]
Western Isles 2.80 [2.40–3.24]
Year 0.00 2002 1.96 [1.53–2.47]
2003 2.48 [2.05–2.97]
2004 2.97 [2.61–3.37]
2005 2.61 [2.28–2.98]
2006 3.27 [2.74–3.87]
Production year 0.00 1st 2.30 [2.00–2.63]
2nd 3.00 [2.60–3.44]
Season 0.00 Spring (Feb–Apr) 3.24 [2.52–4.10]
Summer (May–Jul) 2.13 [1.67–2.67]
Autumn (Aug–Oct) 2.10 [1.75–2.49]
Winter (Nov–Jan) 3.24 [2.61–3.98]
Effective 0.00 No 7.01 [5.95–8.22]
Yes 0.65 [0.55–0.75]
Loch-wide 0.00 No 2.16 [1.89–2.45]
Yes 3.17 [2.79–3.59]
Region6Year 0.00 See Figure 4
Season6Effective 0.00
Season6Loch-wide 0.00
Table indicates those variables found to be statistically significant (p,0.05)
within the model and provides estimates of post-treatment mobile L. salmonis
abundances and their 95% confidence intervals.
#- Forced co-variate with coefficient of 0.16 (95% CI [0.11–0.22])
doi:10.1371/journal.pone.0001549.t004
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appropriate data screening criteria had been applied. While both
of these North American studies presented a snapshot of treatment
efficacy within their respective geographical regions, neither
attempted to show whether the efficacy of emamectin benzoate
had changed over a period of time.
Prospective efficacy studies tend to be based on a relatively small
numbers of treatment episodes. However, they are normally
strictly controlled and often have complete and balanced data sets
collected by a dedicated group of individuals working to a
standard clinical efficacy protocol [20,33]. While laboratory based
studies were essential in establishing the efficacy of emamectin
benzoate, they may not accurately reflect its performance under
commercial conditions. A number of case studies have also been
conducted to assess emamectin benzoate efficacy in the field;
however several had to medicate the untreated ‘‘controls’’ with
alternative ectoparasiticides before the planned completion date in
order to avoid unacceptably high levels of infestation [21,22,34].
Figure 4. Profile plots for treatment episodes showing post-treatment mobile abundances associated with significant (p,0.05)
interaction factors. Post-treatment mobile L. salmonis abundances with associated 95% confidence intervals. Based on a GLM analysis of data from
108 treatment episodes at 47 Atlantic salmon farms in Scotland in the period 2002 to 2006.
doi:10.1371/journal.pone.0001549.g004
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the welfare of fish, but it also complicates the comparability of
subsequent efficacy parameters [28]. Despite the fact that
production data are rarely as complete or balanced as that
collected within a prospective clinical study it can give a better
indication of medicinal efficacy under production conditions and
over a longer period of time, providing sufficient treatment
episodes are available for analysis. While the lice counts in this
study were performed by various individuals on numerous farms, it
should be noted that they were conducted by qualified personnel
who had been given training in this procedure. However, as pre-
treatment lice counts were based on records taken from up to
16 days prior to emamectin benzoate intervention, it is likely that
lice levels were sometimes higher than the baseline figures used in
the efficacy calculations.
All partial site, staggered and mixed treatment episodes were
screened out of this study, but it was important to further
categorise the episodes that were included. Strategic sea lice
treatments form part of the integrated health management
programme adopted by Scottish salmon producers and not all
treatment episodes are administered in response to a substantial
sea lice challenge. It should also be noted that treatment-trigger
guidelines are not uniform amongst countries. Despite the
challenges encountered in classifying treatments as strategic or
ineffective, their inclusion in this study was important as they were
evident throughout the five year period. For the purposes of
analysing loch-wide treatments it was important to ascertain
whether other farm operators treated their respective sites for lice
at the same time as the industrial partner in a coordinated manner.
This information was not always available.
Alternative strategies for assessing the efficacy of emamectin
benzoate were considered, but none was found to be as robust as
the methodology adopted. Counting the number of treatment
interventions in each production cycle or calculating the mean
number of days between treatments gives an indication of
treatment efficacy and lice challenge within a site. However, the
former method is better suited to regions where only one sea lice
medicine is available for use [23] as it is difficult to compare in-
feed emamectin benzoate treatments alone with emamectin
benzoate and topical cypermethrin treatments. Assessing efficacy
over the entire production cycle can also become complicated if
stocks are split between sites for the second year of production or
when the length of time that fish are at sea varies between sites and
years. While useful, these assessments are better suited to macro
level analyses and may be explored in a more general risk factors
study. The purpose of this study was to focus on specific issues
relating to emamectin benzoate interventions in Scotland since
regular treatment began in 2002.
In common with results observed in laboratory and field based
trials conducted in the period 1997 to 2002 [20–22,26,27,33,34],
the majority of emamectin benzoate treatments administered in
this study significantly reduced infestations of mobile L. salmonis.
However, the efficacy of treatments was not uniform between
years or geographical regions. In particular the frequency with
which interventions appeared to be ineffective increased toward
the end of the study period.
Time to maximum efficacy varied widely across episodes, but
generally it was reached 28–34 days post treatment initiation and
overall levels of lice were lowest between days 21 and 62. This is
broadly in line with findings from a recent study on the Maine
coast by Gustafson and colleagues that also used pre-treatment lice
loads to calculate the efficacy of emamectin benzoate [28].
However, it should be noted that of the 19 treatments analysed in
the Gustafson study, all were found to be more than 60%
efficacious and pre-treatment abundance was generally lower,
particularly when compared to the levels observed in Scotland in
2003 and 2004.
Duration of efficacy has been reported to be as long as five
months in the Broughton Archipelago region of British Columbia
[23] although some lice re-infection occurred after three months.
In the current analysis, post-treatment lice levels in Scotland
generally remained below pre-treatment abundance for the full
83 days examined, but began to rise around week nine. It is
interesting to note that, on average, the levels of lice observed prior
to intervention were similar in both studies, but that farms in
British Columbia were re-treated less often than those in Scotland.
However, it is likely that the large populations of migratory Pacific
salmon found in the waters of British Columbia create very
different dynamics in terms of sea lice challenge than those in
Scotland.
The differences found between the present study and that
conducted in Scotland in 2002 [27] are of particular interest. In
the earlier study [27], zero levels of lice were attained for 12–
14 weeks post-treatment, however it should be noted that this
small scale trial involved only two farms and three emamectin
benzoate treatment episodes. Nevertheless, the results presented
herein may indicate that emamectin benzoate is not as effective on
Scottish salmon farms as it once was. Direct comparisons with
other studies are less straightforward, either because efficacy was
monitored over a shorter period of time [22,26,33] or because
untreated cohorts provided a potential source of re-infestation,
that may have extended the time taken to reach maximum efficacy
or reduced the duration of efficacy [21,34].
Previous analysis has shown that since 2002 L. salmonis mobile
abundance tends to vary between geographic regions in Scotland
[19], with farms in the North generally experiencing lower levels of
infestation. The present study shows that post-treatment lice
abundance also differs between regions. Again, levels in the North
were found to be lower and increases in post-treatment abundance
in this region in 2004, and in the Western Isles in 2006, match
similar trends observed in overall mobile lice levels [19]. The peaks
and troughs observed in post-treatment abundance in the South
did not closely match patterns of mobile infestation in this region,
confirming that variables other than year and region are important
and should be considered in a fuller analysis of all risk factors.
It is known that seasonal variation occurs in lice infestation on
Scottish farms and that abundance is generally higher in the
second year of production [13,14,19]. It is perhaps then
unsurprising that post-treatment lice levels also varied throughout
the production cycle in the present study. The univariable analyses
carried out by Gustafson et al [28] found that treatments
administered to larger fish required more time to reach maximum
efficacy. In this multivariable study no significant interaction was
found between production stage and days after treatment, but
post-treatment abundance levels were higher in second year fish.
While the relative performance of emamectin benzoate treatments
across the seasons varied, it appears that post-treatment levels were
highest following winter (Nov–Jan) and spring (Feb–Apr) treat-
ments. Given that all but one of the winter treatments occurred in
the first production year and nearly all spring treatments occurred
in the second, it appears that treatments applied in the middle six
months of the production cycle may not be as efficacious as those
administered during other periods. However, it should be noted
that the distribution of treatments throughout the production cycle
was not balanced. Furthermore, significant interactions were
found between season and effective treatments as well as between
season and loch-wide treatments, making it difficult to conclude
what effect season has on treatment efficacy.
Efficacy of Emamectin Benzoate
PLoS ONE | www.plosone.org 9 February 2008 | Volume 3 | Issue 2 | e1549Reduced sensitivity, and potential resistance, of sea lice to
currently available medicines remains an important area for
continued research. Further analysis regarding the structure of lice
populations prior to and following treatment needs to be
undertaken to assess whether it has any bearing on efficacy. The
prevalence of sea lice following treatment intervention should also
be examined to ascertain whether lice that persist post-treatment
are present on many or few fish within a farm. Studies that
compare alternative treatment strategies across the whole
production cycle are also important [27] as product rotation will
prevent over-dependence on one sea lice medicine and may
discourage resistance in the long term.
The ineffective treatments reported in this study may have
lacked efficacy for a number of reasons relating to fish appetite and
feeding rate, sub-therapeutic dosing due to underestimated
biomass or variation in medicine inclusion level in the feed,
amongst others. In vivo methods for assessing efficacy exist, but the
techniques used for the bioassay of emamectin benzoate require
further validation. Furthermore, the viability of lice post-treatment
is often compromised and therefore improved methods for
enumerating attached individuals, including characterisations such
as ‘‘moribund lice’’ or ‘‘non-viable egg-strings’’, must be developed
[35]. These concerns have led to the establishment of a scientific
group to advise the Scottish salmon industry on a protocol for,
‘‘monitoring sea lice for resistance to approved treatments’’
(Scottish Salmon Producers Organisation, Minutes of the
Integrated Sea Lice Management group, 30
th August, 2007;
Perth, Scotland). In summary, all concerned parties must continue
to closely monitor treatment interventions before a definitive
assessment can be made as to whether the efficacy of emamectin
benzoate against infestations of sea lice on Atlantic salmon farms
in Scotland is diminishing.
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